Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Neoplasms

abstract

  • APC and SN-38 exposure decreased when administered in combination with UCN-01. The MTD of the combination based on protocol criteria was defined as 70 mg/m(2) of UCN-01 on day 1 and 60 mg/m(2) of irinotecan on days 1 and 8 in a 21-day cycle.

publication date

  • March 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3557498

Digital Object Identifier (DOI)

  • 10.1007/s00280-007-0485-9

PubMed ID

  • 17429623

Additional Document Info

start page

  • 423

end page

  • 33

volume

  • 61

number

  • 3